User login
Key clinical point: First-line tiragolumab plus atezolizumab vs. placebo plus atezolizumab is associated with a better objective response rate (ORR) and progression-free survival (PFS) in patients with programmed cell death-ligand 1 (PD-L1)-positive, recurrent, or metastatic nonsmall cell lung cancer (NSCLC).
Major finding: The tiragolumab vs. placebo group demonstrated a superior ORR (31.3% vs. 16.2%; P = .031) and median PFS (5.4 vs. 3.6 months; stratified hazard ratio 0.57; P = .015). The rates of serious treatment-related adverse events in the tiragolumab and placebo groups were 21% and 18%, respectively.
Study details: This phase 2 randomized, double-blind, placebo-controlled CITYSCAPE trial included chemotherapy-naive patients with PD-L1-positive recurrent or metastatic NSCLC (with no EGFR or ALK alterations) who were randomly assigned to receive either tiragolumab plus atezolizumab (n = 67) or placebo plus atezolizumab (n = 68) once every 3 weeks.
Disclosures: The study was funded by F Hoffmann-La Roche and Genentech. M Cobo, N Secen, and X Yang declared no competing interests. The other authors reported ties with one or more pharmaceutical companies, including employment or stock options in the funding companies.
Source: Cho BC et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781-792 (May 13). Doi: 10.1016/S1470-2045(22)00226-1
Key clinical point: First-line tiragolumab plus atezolizumab vs. placebo plus atezolizumab is associated with a better objective response rate (ORR) and progression-free survival (PFS) in patients with programmed cell death-ligand 1 (PD-L1)-positive, recurrent, or metastatic nonsmall cell lung cancer (NSCLC).
Major finding: The tiragolumab vs. placebo group demonstrated a superior ORR (31.3% vs. 16.2%; P = .031) and median PFS (5.4 vs. 3.6 months; stratified hazard ratio 0.57; P = .015). The rates of serious treatment-related adverse events in the tiragolumab and placebo groups were 21% and 18%, respectively.
Study details: This phase 2 randomized, double-blind, placebo-controlled CITYSCAPE trial included chemotherapy-naive patients with PD-L1-positive recurrent or metastatic NSCLC (with no EGFR or ALK alterations) who were randomly assigned to receive either tiragolumab plus atezolizumab (n = 67) or placebo plus atezolizumab (n = 68) once every 3 weeks.
Disclosures: The study was funded by F Hoffmann-La Roche and Genentech. M Cobo, N Secen, and X Yang declared no competing interests. The other authors reported ties with one or more pharmaceutical companies, including employment or stock options in the funding companies.
Source: Cho BC et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781-792 (May 13). Doi: 10.1016/S1470-2045(22)00226-1
Key clinical point: First-line tiragolumab plus atezolizumab vs. placebo plus atezolizumab is associated with a better objective response rate (ORR) and progression-free survival (PFS) in patients with programmed cell death-ligand 1 (PD-L1)-positive, recurrent, or metastatic nonsmall cell lung cancer (NSCLC).
Major finding: The tiragolumab vs. placebo group demonstrated a superior ORR (31.3% vs. 16.2%; P = .031) and median PFS (5.4 vs. 3.6 months; stratified hazard ratio 0.57; P = .015). The rates of serious treatment-related adverse events in the tiragolumab and placebo groups were 21% and 18%, respectively.
Study details: This phase 2 randomized, double-blind, placebo-controlled CITYSCAPE trial included chemotherapy-naive patients with PD-L1-positive recurrent or metastatic NSCLC (with no EGFR or ALK alterations) who were randomly assigned to receive either tiragolumab plus atezolizumab (n = 67) or placebo plus atezolizumab (n = 68) once every 3 weeks.
Disclosures: The study was funded by F Hoffmann-La Roche and Genentech. M Cobo, N Secen, and X Yang declared no competing interests. The other authors reported ties with one or more pharmaceutical companies, including employment or stock options in the funding companies.
Source: Cho BC et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781-792 (May 13). Doi: 10.1016/S1470-2045(22)00226-1